AllianceBernstein
BBIO icon

AllianceBernstein’s BridgeBio Pharma BBIO Stock Holding History

AllianceBernstein’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108M Sell
1,453,504
-455,403
-24% -$31.9M 0.04% 363
2026
Q1 		$146M Sell
1,908,907
-141,839
-7% -$10.3M 0.05% 271
2025
Q4 		$157M Sell
2,050,746
-277,969
-12% -$18.2M 0.05% 274
2025
Q3 		$121M Sell
2,328,715
-141,843
-6% -$6.92M 0.04% 336
2025
Q2 		$107M Sell
2,470,558
-213,588
-8% -$7.77M 0.03% 364
2025
Q1 		$92.8M Sell
2,684,146
-110,146
-4% -$3.71M 0.03% 390
2024
Q4 		$76.7M Sell
2,794,292
-33,374
-1% -$862K 0.03% 481
2024
Q3 		$72M Buy
2,827,666
+375,262
+15% +$9.85M 0.02% 509
2024
Q2 		$62.1M Sell
2,452,404
-391,895
-14% -$10.7M 0.02% 542
2024
Q1 		$87.9M Buy
2,844,299
+286,883
+11% +$9.76M 0.03% 447
2023
Q4 		$103M Sell
2,557,416
-158,724
-6% -$4.77M 0.04% 391
2023
Q3 		$71.6M Buy
2,716,140
+2,560,549
+1,646% +$72.7M 0.03% 468
2023
Q2 		$2.68M Buy
155,591
+22,833
+17% +$344K ﹤0.01% 1745
2023
Q1 		$2.2M Sell
132,758
-200
-0.2% -$2.33K ﹤0.01% 1813
2022
Q4 		$1.01M Hold
132,958
– – ﹤0.01% 2264
2022
Q3 		$1.32M Sell
132,958
-185,258
-58% -$1.92M ﹤0.01% 2142
2022
Q2 		$2.89M Sell
318,216
-38,516
-11% -$322K ﹤0.01% 1729
2022
Q1 		$3.62M Sell
356,732
-60,198
-14% -$618K ﹤0.01% 1740
2021
Q4 		$6.95M Buy
416,930
+279,232
+203% +$11.8M ﹤0.01% 1442
2021
Q3 		$6.45M Buy
137,698
+1,750
+1% +$93.8K ﹤0.01% 1475
2021
Q2 		$8.29M Sell
135,948
-2,410
-2% -$138K ﹤0.01% 1329
2021
Q1 		$8.52M Buy
138,358
+34,374
+33% +$2.25M ﹤0.01% 1280
2020
Q4 		$7.39M Hold
103,984
– – ﹤0.01% 1283
2020
Q3 		$3.9M Sell
103,984
-2,433
-2% -$76.6K ﹤0.01% 1472
2020
Q2 		$3.47M Buy
106,417
+6,800
+7% +$207K ﹤0.01% 1538
2020
Q1 		$2.89M Buy
99,617
+72,164
+263% +$2.24M ﹤0.01% 1463
2019
Q4 		$962K Buy
+27,453
New +$761K ﹤0.01% 2296

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

AllianceBernstein's BBIO Position: Q2 2026 in Review

AllianceBernstein reduced its BridgeBio Pharma (BBIO) stake by 24% in Q2 2026, selling an estimated $31.9M and leaving 1,453,504 shares worth $108M. The position accounts for 0.04% of the portfolio, ranked #363.

AllianceBernstein first reported a position in BBIO in Q4 2019 and has held it in 27 quarters since. The position peaked at $157M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • AllianceBernstein held 1,453,504 shares of BridgeBio Pharma worth $108M as of Q2 2026.
  • AllianceBernstein sold 455,403 BridgeBio Pharma shares in Q2 2026, an estimated $31.9M.
  • BridgeBio Pharma made up 0.04% of AllianceBernstein's portfolio in Q2 2026, its #363 holding.
  • AllianceBernstein first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 27 quarters since.
  • AllianceBernstein's BridgeBio Pharma position peaked at $157M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.